Protein expression of p53, Ki-67, and bcl2 were evaluated in archival paraffin-embedded radical prostatectomy specimens from 162 patients of clinically localized cancer by Moul et al [124] to determine the clinical use of p53, Ki-67, and bcl2 immunohistochemical protein expression in the primary tumour as combined predictors of disease progression. The gene discussed is BCL2; the disease is cancer.